Literature DB >> 8232357

Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.

P E Greene1, S Fahn.   

Abstract

Fifteen patients with torticollis who had been treated with repeated injections of botulinum toxin type A (botox A) developed antibodies to the toxin. This resulted in loss of benefit in the 13 patients who had improved with botox A injections and failure to develop muscle atrophy after injection in all 15 patients. Patients were then injected with botulinum toxin type F (botox F) in the same muscles that had been injected with botox A. Ten of the 15 improved after botox F injections, including 9 of the 12 patients who had improved with type A toxin. Six of 9 patients with pain had improvement in pain after botox F injections. Patients reported similar improvement with type F and type A toxins, but duration of benefit was approximately 3 months with type A and approximately 1 month with type F. Botox F is an effective treatment for torticollis in patients who are immune to botox A. The usefulness of type F toxin, however, is limited by short duration of benefit.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232357     DOI: 10.1002/mds.870080411

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.

Authors:  R Eleopra; V Tugnoli; R Quatrale; O Rossetto; C Montecucco; D Dressler
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

3.  Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E: use of hapten-labeled-antibody elution to isolate specific complexes.

Authors:  G J Doellgast; J E Brown; J A Koufman; C L Hatheway
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

Review 4.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

5.  Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").

Authors:  Sabine Pellett; William H Tepp; Guangyun Lin; Eric A Johnson
Journal:  Toxicon       Date:  2017-12-19       Impact factor: 3.033

6.  Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.

Authors:  M K Houser; G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

7.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

Review 8.  New concepts in botulinum toxin therapy.

Authors:  G E Borodic; L B Pearce
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

9.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

10.  Botulinum toxin type A in the treatment of patients with cervical dystonia.

Authors:  Allison Brashear
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.